Table 1.
Baseline characteristics of DLBCL patients who received auto-HCT or CAR-T while in a PR
| Auto-HCT | CAR-T | P value* | |
|---|---|---|---|
| Number of patients† | 266 | 145 | |
| Number of centers | 88 | 40 | |
| Demographics | |||
| Patient age | |||
| Median, y (range) | 58 (18-80) | 60 (24-91) | .07‡ |
| ≥60 y (%) | 118 (44) | 73 (50) | .25§ |
| Male sex | 167 (63) | 89 (61) | .78§ |
| Race | <.001§ | ||
| Caucasian | 166 (62) | 123 (83) | |
| African American | 58 (22) | 10 (7) | |
| Other‖ | 11 (4) | 1 (1) | |
| Missing | 11(4) | 7 (5) | |
| At diagnosis | |||
| Stage at diagnosis | .99§ | ||
| III-IV, no. (%) | 163 (61) | 80 (55) | |
| Missing | 42 (16) | 35 (24) | |
| High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements, no. (%) | 10 (16) | 25 (17) | .84§ |
| Missing (not collected before 2018) | 204 | ||
| LDH elevated at diagnosis | 74 (28) | 37 (26) | .53§ |
| Missing | 152 (57) | 92 (63) | |
| Extranodal involvement at diagnosis, no. (%) | 136 (51) | 72 (50) | .51§ |
| Missing | 42 (16) | 19 (13) | |
| Prior treatments | |||
| Refractory to first-line therapy, no. (%) | 160 (60) | 79 (55) | .61§ |
| Missing | 6 (2) | 22 (15) | |
| Time from diagnosis to auto-HCT or CAR-T, mo, no. (%) | .30§ | ||
| ≤12 mo | 103 (39) | 64 (44) | |
| >12 mo | 162 (61) | 81 (56) | |
| Missing | 1 (0) | 0 | |
| Lines of therapy before auto-HCT or CAR-T | |||
| Median (range) | 2 (1-6) | 3 (2-11) | <.001‡ |
| More than 2 lines, no. % | 89 (33) | 97 (67) | <.001§0 |
| Number of prior treatment lines | |||
| 1 | 48 (18) | 0 | |
| 2 | 124 (47) | 42 (29) | |
| 3 | 55 (21) | 52 (36) | |
| 4 | 22 (8) | 23 (16) | |
| 5 or more | 12 (4) | 22 (15) | |
| Missing | 5 (2) | 6 (4) | |
| Pre auto-HCT or CAR-T | |||
| KPS | .09§ | ||
| ≥90 | 136 (51) | 56 (39) | |
| Missing | 2 (3) | 13 (9) | |
| Largest node before auto-HCT or CAR-T, no. (%) | .05§ | ||
| <3 cm | 41 (15) | 21 (15) | |
| 3-5 cm | 65 (24) | 26 (18) | |
| >5 cm | 76 (29) | 60 (41) | |
| Missing | 84 (32) | 38 (26) | |
| Imaging before auto-HCT or CAR-T, no. (%) | .36§ | ||
| PET or PET/CT | 222 (83) | 126 (87) | |
| CT | 44 (17) | 19 (13) | |
| Conditioning regimen, no. (%) | |||
| BEAM | 203 (76) | N/A | |
| Bu/Cy | 15 (6) | N/A | |
| CBV | 43 (16) | N/A | |
| Other | 43 (16) | N/A | |
| Lymphodepletion regimen, no. (%) | |||
| Flu/Cy | N/A | 145 (100) | |
| Year of auto-HCT or CAR-T, no. (%) | <.001§ | ||
| 2018 and after | 66 (20) | 145 (100) | |
| Follow-up, median, mo (range) | 38 (3-79) | 12 (3-26) |
BEAM, carmustine, etoposide, cytarabine and melphalan; Bu/Cy, busulfan/cyclophosphamide; CBV, cy, carmustine, etoposide; CT, computed tomography; Flu/Cy, fludarabine, cyclophosphamide; KPS, Karnofsky performance score; LDH, lactate dehydrogenase.
*
P values were calculated ignoring the missing values.
†
This includes 11 patients with primary mediastinal large B-cell lymphomas in the auto-HCT group and 4 in the CAR-T therapy group.
‡
Hypothesis testing Kruskal-Wallis test.
§
Hypothesis testing Pearson χ2 test.
‖
Patient race – other: auto-HCT: 1 native Hawaiian or other Pacific islander, 5 American Indian or Alaska Native, 5 more than 1 race. CAR-T: 1 more than 1 race.